Patent US4719203A successfully refreshed from Google Patents.
US4719203A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
Assignee: Roche Diagnostics GmbH
•
Filing: 1986-11-12
•
Granted: 1988-01-12
•
Expires: 2006-11-12
Abstract
Abstract Diphosphonate compounds, processes for their preparation and pharmaceutical compositions containing them and being useful for treating calcium metabolism disorders. The diphosphonates are of the formula <IMAGE> (I) wherein R1 and R2 are hydrogen, acyl or alkyl which can be substituted by aryl, R3 and R4 are hydrogen or alkyl or R3 and R4 together represent lower alkylene, R5 is a hydrogen atom or alkyl, X is a valency bond or alkylene, Y is a valency bond, alkylene or substituted alkylene, Z is hydrogen, hydroxyl or amino group optionally substituted by alkyl and n is 1, 2 or 3; and including the pharmacologically acceptable salts thereof.
Inventors
- 👤 Elmar Bosies
- 👤 Rudi Gall
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 14:50
CPC Classifications
C; C07; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/38; C07F9/40; C07F9/4003; C07F9/4025; C07F9/405; A; A61; A61P; A61P3/00; A61P3/02; A61P3/12; A61P3/14; C07F9/3804; C07F9/3839; C07F9/3873
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
149 words
A diphosphonate of the formula ##STR13## wherein R 1 and R 2 , which can be the same or different, are hydrogen, C 2 -C 5 acyl, C.sub. -C 4 alkyl or C.sub. -C 4 alkyl substituted by aryl, pyridyl, imidazolyl or thienyl, R 3 and R 4 , which can be the same or different, are hydrogen or C.sub. -C 4 alkyl or R 3 and R 4 together represent alkylene with up to 4 carbons, R 5 is hydrogen or C.sub. -C 4 alkyl, X is a valency bond or alkylene with up to 4 carbons, Y is a valency bond, C.sub. -C 4 alkylene or C.sub. -C 4 alkylene substituted by --NR 1 R 2 , in which R 1 and R 2 have the same meanings as above, Z is hydrogen, or hydroxy and n is 1, 2 or 3; or the pharmacologically salts thereof.
Claim 2
Dependent Claim
149 words
A diphosphonate of the formula ##STR13## wherein R 1 and R 2 , which can be the same or different, are hydrogen, C 2 -C 5 acyl, C.sub. -C 4 alkyl or C.sub. -C 4 alkyl substituted by aryl, pyridyl, imidazolyl or thienyl, R 3 and R 4 , which can be the same or different, are hydrogen or C.sub. -C 4 alkyl or R 3 and R 4 together represent alkylene with up to 4 carbons, R 5 is hydrogen or C.sub. -C 4 alkyl, X is a valency bond or alkylene with up to 4 carbons, Y is a valency bond, C.sub. -C 4 alkylene or C.sub. -C 4 alkylene substituted by --NR 1 R 2 , in which R 1 and R 2 have the same meanings as above, Z is hydrogen, or hydroxy and n is 1, 2 or 3; or the pharmacologically salts thereof.
Claim 3
Dependent Claim
78 words
The diphosphonate of claim 1, wherein R 1 and R 2 , which can be the same or different, are hydrogen, methyl or acetyl, R 3 and R 4 , which can be the same or different, are hydrogen or methyl, R 5 is hydrogen, X and Y, which can be the same or different, are valency bonds, methylene or ethylene Z, is a hydroxy group and n is 1 or 2, or the pharmacologically acceptable salts thereof.
Claim 4
Dependent Claim
14 words
The diphosphonate of claim 1 wherein R 1 is methyl, ethyl, isopropyl or acetyl.
Claim 5
Dependent Claim
20 words
The diphosphonate of claim 1 wherein R 1 is C.sub. -C 4 alkyl substituted by phenyl, pyridyl, imidazolyl or thienyl.
Claim 6
Dependent Claim
14 words
The diphosphonate of claim 1 wherein X is a valence bond, methylene or ethylene.
Claim 7
Dependent Claim
19 words
The diphosphonate of claim 1 wherein R 5 is hydrogen, Y is methylene or ethylene and Z is hydroxy.
Claim 8
Dependent Claim
11 words
The diphosphonate of claim 1 wherein Y is methylene or ethylene.
Claim 9
Dependent Claim
9 words
The diphosphonate of claim 1 designated 3-(2-acetylaminocyclohexyl)-1-hydroxypropane-1, 1-diphosphonic acid.
Claim 10
Dependent Claim
9 words
The diphosphonate of claim 1 designated 2-(2-aminomethylcyclohexyl)-1-hydroxyethane-1, 1-diphosphonic acid.
Claim 11
Dependent Claim
9 words
The diphosphonate of claim 1 designated cis-3-(2-aminocyclohexyl)-1-hydroxypropane-1, 1-diphosphonic acid.
Claim 12
Dependent Claim
9 words
The diphosphonate of claim 1 designated 3-(1-aminocyclohexyl)-1-hydroxypropane-1, 1-diphosphonic acid.
Claim 13
Dependent Claim
9 words
The diphosphonate of claim 1 designated 3-(2-aminocyclohexyl)-1-hydroxypropane-1, 1-diphosphonic acid.
Claim 14
Dependent Claim
9 words
The diphosphonate of claim 1 designated 3-(2-Aminocyclopentyl)-1-hydroxypropane-1, 1-diphosphonic acid.
Claim 15
Dependent Claim
22 words
A pharmaceutical composition comprising an effective amount of diphosphonate of claim 1 in a pharmaceutically acceptable carrier for treating calcium metabolism disorders.
Claim 16
Dependent Claim
14 words
The pharmaceutical composition of claim 14 containing 1 to 1000 mg of said diphosphonate.
Claim 17
Dependent Claim
14 words
The pharmaceutical composition of claim 14 containing 10 to 200 mg of said diphosphonate.
Claim 18
Dependent Claim
29 words
The pharmaceutical composition of claim 14 wherein said diphosphonate is 3-(2-acetylaminocyclohexyl)-1-hydroxypropane-1, 1-diphosphonic acid; 2-(2-aminomethylcyclohexyl)-1-hydroxyethane-1, 1-diphosphonic acid; cis-3-(2-aminocyclohexyl)-1-hydroxypropane-1, 1-diphosphonic acid; 3-(1-aminocyclohexyl)-1-hydroxypropane-1, 1-diphosphonic acid; 3-(2-aminocyclohexyl)-1-hydroxypropane-1, 1-diphosphonic acid; or 3-(2-Aminocyclopentyl)-1-hydroxypropane-1, 1-diphosphonic acid.
Claim 19
Dependent Claim
18 words
A method for treating calcium metabolism disorders comprising administering, enterally or parenterally, the pharmaceutical composition of claim 14.
Claim 20
Dependent Claim
21 words
A method for treating calcium metabolism disorder comprising administering, enterally or parenterally, an effective amount of the diphosphonate of claim 1.
Claim 21
Dependent Claim
15 words
The method of claim 19 wherein 1 to 1000 mg of the diphosphonate, are administered.
References Cited (Backward Citations)
DE1002355B
Cited
US3299123A
Cited
US3617343A
Cited
US3962432A
Cited
US4054598A
Cited
US4064164A
Cited
US4267108A
Cited
US4407761A
Cited
US4304734A
Cited
US4624947A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-01-11 | 1991-07-13 | 1992-01-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-01-11 | 1995-07-13 | 1996-01-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-01-11 | 1999-07-13 | 2000-01-12 | $7700.00 | Window Closed / Lapsed |